Matthew Gdovin, an associate professor in the UTSA Department of Biology, has developed a newly patented method to kill cancer cells. His discovery, described in research published in The Journal of Clinical Oncology, may tremendously help people with inoperable or hard-to-reach tumors, as well as young children stricken with cancer.
Gdovin’s top-tier research involves injecting a chemical compound, nitrobenzaldehyde, into the tumor and allowing it to diffuse into the tissue. He then aims a beam of light at the tissue, causing the cells to become very acidic inside and, essentially, commit suicide. Within two hours, Gdovin estimates up to 95 percent of the targeted cancer cells are dead.
“Even though there are many different types of cancers, the one thing they have in common is their susceptibility to this induced cell suicide,” he said.
Gdovin tested his method against triple negative breast cancer, one of the most aggressive types of cancer and one of the hardest to treat. The prognosis for triple negative breast cancer is usually very poor. After one treatment in the laboratory, he was able to stop the tumor from growing and double chances of survival in mice.
“All forms of cancer attempt to make cells acidic on the outside as a way to attract the attention of a blood vessel, which attempts to get rid of the acid,” he said. “Instead, the cancer latches onto the blood vessel and uses it to make the tumor larger and larger.”
Chemotherapy treatments target all cells in the body, and certain chemotherapeutics try to keep cancer cells acidic as a way to kill the cancer. This is what causes many cancer patients to lose their hair and become sickly. Gdovin’s method, however, is more precise and can target just the tumor.
In the past two years, he’s developed his photodynamic cancer therapy to the point where it’s non-invasive. It now requires just an injection of the nitrobenzaldehyde fluid followed by a flash of an ultraviolet light to cause the cancer-killing reaction. Gdovin has now begun to test the method on drug-resistant cancer cells to make his therapy as strong as possible. He’s also started to develop a nanoparticle that can be injected into the body to target metastasized cancer cells. The nanoparticle is activated with a wavelength of light that it can pass harmlessly through skin, flesh and bone and still activate the the cancer-killing nanoparticle.
Gdovin hopes that his non-invasive method will help cancer patients with tumors in areas that have proven problematic for surgeons, such as the brain stem, aorta or spine. It could also help people who have received the maximum amount of radiation treatment and can no longer cope with the scarring and pain that goes along with it, or children who are at risk of developing mutations from radiation as they grow older.
“There are so many types of cancer for which the prognosis is very poor,” he said. “We’re thinking outside the box and finding a way to do what for many people is simply impossible.”
Learn more: UTSA researcher develops new, non-invasive method to wipe out cancerous tumors
The Latest on: Photodynamic cancer therapy
[google_news title=”” keyword=”Photodynamic cancer therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Photodynamic cancer therapy
- Hospital is first in WNY to offer noninvasive prostate cancer therapyon May 9, 2024 at 1:00 pm
Administered using advanced robotics, the treatment offers a new option for men who previously were candidates only for active surveillance.
- I Had Cancer. My Treatment Was Eye-Opening About Addictionon May 9, 2024 at 6:14 am
I've had two different types of cancer in two years and in both instances, I was screened, diagnosed early, and ushered into care.
- ImPact Biotech Presents Preliminary Phase 3 Results from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Canceron May 6, 2024 at 5:00 am
Encouraging response rate shown; CR in 67% (6/9) of patients who completed the Induction Treatment Phase Padeliporfin VTP generally well-tolerated, consistent with prior results and reinforcing ...
- Researchers develop tiny droplets that harness laser light to detect disease markerson April 29, 2024 at 7:19 am
A team of researchers led by Nanyang Technological University, Singapore (NTU Singapore) has created tiny droplets that, when activated by laser light, can detect viral protein biomarkers indicating ...
- Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDTon April 21, 2024 at 5:00 pm
Patients with actinic keratosis reported more intense pain with red light photodynamic therapy (PDT) compared with simulated daylight PDT (SDL-PDT), according to recent study findings. The results ...
- Advanced Nanotechnology Leading the way to Cancer Imaging and Treatmenton April 7, 2024 at 12:47 am
Cancer remains a significant and debilitating disease, posing a formidable challenge to human health, and its incidence continues to rise steadily. The urgency to address this pressing issue has ...
- Kintara (KTRA) Stock Soars on Merger Agreement With TuHURAon April 4, 2024 at 8:45 am
a second-generation photodynamic therapy photosensitizer agent for the treatment of cutaneous metastatic breast cancer. Meanwhile, TuHURA is developing its lead personalized cancer vaccine ...
- New synthesis platform allows for rapid cancer drug synthesis and testingon April 1, 2024 at 7:11 am
"For an agent to be effective for photodynamic therapy, it should be completely ... and its efficiency when killing cancer cells exposed to light. They then used the information to design a ...
- Ovarian Cancer Resource Centeron April 27, 2023 at 4:12 am
Ovarian cancer starts in one or both ovaries, or in the fallopian tubes, or in the abdominal lining called the peritoneum. Women between the ages of 55 and 63 are most likely to get ovarian cancer.
- Lung Cancer Resource Centeron December 2, 2022 at 10:34 am
As you go through lung cancer treatment, you’ll have a whole team of professionals ensuring that you’re getting quality care. Finding out you have lung cancer can be overwhelming. Use this ...
via Bing News